Pharmaceutical Technology
FEBRUARY 24, 2023
Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. Douglas collaborates with scientific researchers and external medical experts to advance clinical research.
Pharmaceutical Technology
FEBRUARY 24, 2023
Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. Douglas collaborates with scientific researchers and external medical experts to advance clinical research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 16, 2022
Everest has meanwhile also filed for approval of the drug in the same indication with regulators in South Korea, Taiwan and Hong Kong. “Trodelvy is the cornerstone of our solid tumour portfolio,” commented Bill Grossman, Gilead’s head of oncology clinical research.
Olympian Clinical Research
JULY 12, 2022
Serotonin is a neurotransmitter that plays a role in mood regulation. This type of depression may occur after childbirth and is thought to be caused by a sudden hormone change. PMDD is thought to be caused by a combination of hormonal and brain chemistry changes. Olympian Clinical Research frequently hosts studies on depression.
XTalks
SEPTEMBER 17, 2020
In rare disease trials, it’s not always feasible to choose clinically-relevant endpoints to measure the efficacy of a new therapeutic. Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. Acromegaly. Prevalence: 50 to 70 people per 1 million.
The Pharma Data
DECEMBER 15, 2020
It is funded by the world’s leading charities dedicated to diabetes research, JDRF, and Diabetes UK, guided by both organizations’ strong commitment to facilitate deep interrogation of consolidated community-wide trial data as a means to accelerate clinical research and therapeutic development for T1D.
Drug Discovery World
FEBRUARY 20, 2023
Novartis’ Lutetium-177 PSMA-617 is limited to cases carrying the surface molecule PSMA (prostate specific membrane antigen) and in patients who had previously received chemotherapy and who do not respond to hormone withdrawal.
Expert insights. Personalized for you.
100 
Let's personalize your content